Compass Therapeutics reported a net loss of $27.2 million for the third quarter of 2026, driven by significantly higher manufacturing and pre-commercialization expenses for its lead candidate, tovecimig. The company maintains a liquidity position of $163 million, which management expects will fund operations into 2028.

Key Highlights

  • Research and development expenses surged 72% to $22.0 million, primarily due to $8.6 million in tovecimig manufacturing costs to support regulatory filings.
  • Clinical data from the COMPANION-002 study showed tovecimig plus paclitaxel achieved an 18.0% ORR and a 56% reduction in the risk of disease progression (HR=0.44).
  • Management is actively engaging the FDA regarding a BLA submission for biliary tract cancer, despite an agency recommendation for an additional survival study.